Clinical Trials (Phase IV)
Found 3,408 articles
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
The majority of clinical trials are conducted at major research institutions or clinics, often based in urban areas. This can create problems.
Help us identify the leading employers in the life science industry! We want to uncover who leads in key areas like diversity, culture, unique benefits and, of course, who are the 2019 Life Sciences Ideal Employers.
Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis
Pfizer Inc. (NYSE:PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.
Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Eli Lilly and Company announced that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head study in patients with active psoriatic arthritis as a late-breaking abstract at the European Congress of Rheumatology in Madrid, Spain on June 15.
New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
Bristol-Myers Squibb Company (NYSE:BMY) today announced data from a Phase IV mechanistic study exploring differences in the cellular and molecular mechanisms by which ORENCIA® (abatacept) and another treatment, adalimumab, interfere with disease progression in moderate-to-severe early rheumatoid arthritis (RA) patients seropositive for certain autoantibodies
All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)
Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR¹ at Week 12
Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor
Results to be Presented During a Late-Breaking Oral Session at the Annual European Congress of Rheumatology (EULAR 2019)
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union
CarvaNum® is the Company’s Fifth E.U. Notified Product
Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)
Mallinckrodt plc, a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel in patients with persistently active rheumatoid arthritis who were previously treated with disease-modifying anti-rheumatic drugs and corticosteroids.
Final analysis of SLU01 data confirmed promising clinical efficacy of DCVAC/LuCa active cellular immunotherapy product in patients with stage IV non-small cell lung cancer.
Innovative external fixator shortens surgical time, simplifies inventory, and enhances patient care.
Allegro Ophthalmics Announces Positive Results of Ex-U.S. Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease
Results of the Trial Suggest that ALG-1007 is Well-Tolerated and Demonstrates a Dose Response with Improvement as Early as Two Weeks
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Observational registry (at midway point) with retrospective data collection provides preliminary evaluation of premature versus term and near-term neonates with pulmonary hypertension receiving inhaled nitric oxide
New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin
Data Presented at the American Urological Association 2019 Annual Meeting
Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population
Company continues focus on evidence expansion, potential utility of Acthar Gel in appropriate, underserved patients
4/17/2019The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them.
RCT DUPLICATE adds new studies to inform FDA - the first to use real-world evidence to predict treatment safety and efficacy